Simon May: I still think we feel good about the position. I mean, we’ve made no secret of the fact that the competitive landscape is intensified. And as we reflect on Q3, I think as we called out in the scripts, we had a couple of really notable wins there that we think are going to help continue to position us well for the future. I think what we really saw in Q3, again, is an exacerbation of these biopharma impacts. We have put secular strength in the early biotech sector. And I think what we saw in Q3 was a cumulative impact of these deferred projects and layoffs in the continuing extremely tight budget environment. Once again, we’re seeing a lot of interest in the products, but the money is just not flowing. We continue to see healthy adoption and really strong acceptance of our QX600 platform.
So, as we look to the future, if we all believe that these impacts in biopharma transient and when we emerge from it, we think we’re going to be in a really strong position. And then, of course, we’ve got competitors who are playing more in the lower end segments, and we plan to enter there with the QX Continuum platform in 2024. So for sure, the competitive pressure is intensifying, but I think we’ve got compelling responses and where we’ve got leading positions in these segments will continue to do well as and when these markets recover.
Conor McNamara: And just a quick follow-up on pricing. And I guess this is across everything in Life Sciences. What’s the pricing environment like? And how should we think about that going forward?
Andy Last: Yes. I think that the environment is still inflationary. As you probably appreciate, on the clinical side, tender-driven business, you can only take very modest and periodic price increases. And we do that when we get that opportunity. On Life Science, there is still inflationary effect and we will still look to try and take modest price increases as we move forward to help offset our inflationary pressures that we’re receiving. And we expect to do — we’ve done that this year. We expect to do that next year. And I think in the quarter, we probably got just over 1 point of price, 1.5 points of price on a net basis and think that that should at least be a floor.
Simon May: We’ve seen a mix impact there with process chrom as well.
Andy Last: Yes.
Conor McNamara: Okay. And just a final question. This for Norm. Just given the recent selloff in the space and specifically in your stock, how does that change your acquisition strategy, if at all? And would you still consider issuing equity to pursue an acquisition target in this environment?
Norman Schwartz: So I think that kind of in light of the recent stock dislocation, I think we will very much consider continuing our share repurchases as part of our capital allocation strategy and obviously, at this point, not such a good currency for M&A. I think, in fact, while we do continue to kind of look at opportunities, I think it’s probably fair to say that more of our focus over the next several quarters will be centered around kind of navigating our markets and our continued operational transformation.
Operator: There are no further questions at this time. I would like to turn it back to Edward Chung for further remarks.
Edward Chung: Thank you for joining today’s call. As always, we appreciate your interest, and we look forward to connecting soon. Thanks, operator.
Operator: Thank you. And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.
